It's a win-win for both sides, assuming there is a
Post# of 11802
What if I told you that a technical manager in the M&A area has been assigned, a scientific writer engaged, and at the end of the technological review DECN will be able to publish the non-proprietary parts of the review, several industry experts not in competitive positions were interviewed early in the process. No matter what the penny traders and faux biotech and IP experts tell you, because they are liars and frauds and message board criminals, GenUltimate TBG is a big, big deal and choosing to make the marked improvement in GenUltimate rather than coming out with a newer technology product (which they also designed) was pure strategic magic.
But you know what, GenUltimate TBG isn't all about stock price so at best I consider the new product of the decade to be at best ho-hum among DECN message board posters.